- Home
- FENC vs USNA Comparison
FENC vs USNA Comparison
Compare FENC & USNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FENC | USNA |
|---|---|---|
| Founded | 1996 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 366.8M | 397.1M |
| IPO Year | 2010 | 1996 |
Fundamental Metrics
Financial Performance| Metric | FENC | USNA |
|---|---|---|
| Price | $10.75 | $14.09 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $17.20 | N/A |
| AVG Volume (30 Days) | 122.5K | ★ 182.7K |
| Earning Date | 11-12-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | $44,642,000.00 | ★ $1,060,902,000.00 |
| Revenue This Year | $62.55 | N/A |
| Revenue Next Year | $42.10 | $3.96 |
| P/E Ratio | $164.92 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.65 | $12.57 |
| 52 Week High | $13.25 | $23.59 |
Technical Indicators
Market Signals| Indicator | FENC | USNA |
|---|---|---|
| Relative Strength Index (RSI) | 52.81 | 45.01 |
| Support Level | $9.87 | $13.80 |
| Resistance Level | $11.07 | $15.87 |
| Average True Range (ATR) | 0.67 | 0.68 |
| MACD | 0.00 | -0.06 |
| Stochastic Oscillator | 73.17 | 54.74 |
Price Performance
Historical ComparisonAbout FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About USNA USANA Health Sciences Inc.
Usana Health Sciences Inc develops and manufactures high-quality nutritional supplements, functional foods, and personal care products that are sold throughout the world. The company has developed and manufactured high-quality, science-based nutritional, personal care, and skincare products with a primary focus on promoting long-term health and wellness. The Company's reporting units for goodwill purposes are tied to its reportable segments: Core nutritional and Hiya direct-to-consumer. The core nutritional segment consists of three individual reporting units that are determined based on the operational nature of the business: Buy-Sell, China, and India. Geographically, it is in Asia Pacific, the Americas, and Europe. With the majority of revenue from Asia Pacific(Greater China).